efinopegdutide vs Zabopegdutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline

efinopegdutide

Developed by Merck & Co.

Phase 2 in MASH / NASHpeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in MASH / NASHpeptide
Partial signal

NCT06410924 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.

Reported efficacy

Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF (12 weeks): Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. (met)

Result source: NCT06410924

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointefinopegdutideZabopegdutide
MASH resolution without fibrosis worsening—Not reported—Not reported
Fibrosis stage, change—Not reported—Not reported
Liver fat (MRI-PDFF), change—Not reported—Not reported
ALT, change—Not reported—Not reported

MASH resolution without fibrosis worsening

efinopegdutide
—Not reported
Zabopegdutide
—Not reported

Fibrosis stage, change

efinopegdutide
—Not reported
Zabopegdutide
—Not reported

Liver fat (MRI-PDFF), change

efinopegdutide
—Not reported
Zabopegdutide
—Not reported

ALT, change

efinopegdutide
—Not reported
Zabopegdutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

efinopegdutide: no structured comparison results are available for MASH / NASH.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zabopegdutide

MRI-PDFF ≥30% 75.8% vs 11.8% placebo @ 12wk
responder rate · % of participants
NCT06410924 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efinopegdutide's landscape · Zabopegdutide's landscape